Comparison of oncologic outcome of preoveratively presumed low-risk endometrial cancer patients who underwent only bilateral pelvic sentinel lymph node (SLN) removal and those who underwent pelvic lymphadenectomy in addition to bilateral pelvic SLN removal: Turkish Gynecologic Oncology Group (TRSGO-SLN-009)
Journal of Gynecologic Oncology · 2026
DOI: 10.3802/jgo.2026.37.e23 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Gynecologic Oncology, 2026. Verfasst von Tugan Bese und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Istanbul University-Cerrahpasa Cerrahpasa Faculty of Medicine, Istanbul, T…. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Lymph Node Excision, Sentinel Lymph Node, Carcinoma, Endometrioid. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
OBJECTIVE: We aimed to compare the oncological outcomes of patients with bilateral sentinel lymph nodes (SLNs) detection and removed with those who underwent pelvic lymphadenectomy (PLA) in addition to bilateral SLNs removal. METHODS: This multicenter, retrospective study included cases of endometrioid type, grade I-II endometrial cancer, in which bilateral SLNs were detected and removed. Patients who had only bilateral SLNs detected and removed (group I) and patients who had bilateral SLNs detected and removed and subsequent additional bilateral PLA (group II) were included in the evaluation. RESULTS: In group I (n=216), SLN metastasis rate was 5.5% and in group II (n=251), it was 10.3%. The low-volume disease detection rate was 4.6% in group I and 4.8% in group II. In group II, in patients with SLN macrometastasis had also 28.6% non-SLN macrometastasis. No false-negative results occurred in group II. Recurrence was detected 1.8% in group I and 5% in group II; however, there was no significant difference (p=0.083). Disease-free survival and overall survival, were almost same between the groups (hazard ratio [HR]=2.11; 95% confidence interval [CI]=0.681-6.588; p=0.187) and (HR=1.531; 95% CI=0.392-5.975; p=0.537), respectively. CONCLUSION: SLN mapping, ultrastaging, and immunohistochemical staining can identify low-volume metastases that may not be identified with classic lymphadenectomy and hematoxylin & eosin staining. It has been observed that adding PLA beyond SLN mapping did not provide an additional positive contribution to survival. For endometriod type grade I-II patients, detection of bilateral SLNs in both hemipelvis only, if detectable, is an adequate approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Istanbul University-Cerrahpasa Cerrahpasa Faculty of Medicine, Istanbul, Turkey.
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Istanbul University-Cerrahpasa Cerrahpasa Faculty of Medicine, Istanbul, Turkey. sukrucebi@gmail.com.
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ankara University School of Medicine, Ankara, Turkey.
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Koc University School of Medicine Istanbul, Istanbul, Turkey.
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Okmeydanı Training and Research Hospital, Istanbul, Turkey.
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Istanbul Teaching and Research Hospital, Istanbul, Turkey.
ORCID-Profile: Tugan Bese, Sait Sukru Cebi, Salih Taskin, Cagatay Taskiran, Dogan Vatansever, Firat Ortac, Nedim Tokgozoglu, Hasan Turan, İlker Kahramanoglu, Mete Gungor, Faruk Kose, Macit Arvas, Fuat Demirkiran
Zitieren
APA
Bese, T., Cebi, S. S., Taskin, S., Taskiran, C., Vatansever, D., Ortac, F., Tokgozoglu, N., Turan, H., Kahramanoglu, İ., Gungor, M., Kose, F., Arvas, M., & Demirkiran, F. (2026). Comparison of oncologic outcome of preoveratively presumed low-risk endometrial cancer patients who underwent only bilateral pelvic sentinel lymph node (SLN) removal and those who underwent pelvic lymphadenectomy in addition to bilateral pelvic SLN removal: Turkish Gynecologic Oncology Group (TRSGO-SLN-009). Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2026.37.e23
Vancouver
Bese T, Cebi SS, Taskin S, Taskiran C, Vatansever D, Ortac F, et al. Comparison of oncologic outcome of preoveratively presumed low-risk endometrial cancer patients who underwent only bilateral pelvic sentinel lymph node (SLN) removal and those who underwent pelvic lymphadenectomy in addition to bilateral pelvic SLN removal: Turkish Gynecologic Oncology Group (TRSGO-SLN-009). Journal of Gynecologic Oncology. 2026. doi:10.3802/jgo.2026.37.e23
BibTeX
@article{Bese2026,
author = {Bese, Tugan and Cebi, Sait Sukru and Taskin, Salih and Taskiran, Cagatay and Vatansever, Dogan and Ortac, Firat and Tokgozoglu, Nedim and Turan, Hasan and Kahramanoglu, İlker and Gungor, Mete and Kose, Faruk and Arvas, Macit and Demirkiran, Fuat},
title = {Comparison of oncologic outcome of preoveratively presumed low-risk endometrial cancer patients who underwent only bilateral pelvic sentinel lymph node (SLN) removal and those who underwent pelvic lymphadenectomy in addition to bilateral pelvic SLN removal: Turkish Gynecologic Oncology Group (TRSGO-SLN-009)},
journal = {Journal of Gynecologic Oncology},
year = {2026},
doi = {10.3802/jgo.2026.37.e23}
}
EUVIMED